Back to Awarded Treatment Trials
Awarded Trial: 01-043
Grant ID
01-043
Illness
Schizophrenia
Primary Drug/Intervention
Risperidone added to Clozapine
Primary Dosage
4mg
Secondary Drug Intervention
Clozapine monotherapy
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Freudenreich
Sample Size
24
Duration of Study Period for Each Subject
6 weeks
Outcome Measurements
PANSS, SANS
Results
Twenty-four patients were randomized to receive adjunctive risperidone or placebo. There were no significant differences observed between groups.
Publication
Freudenreich, O et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial. Schizophrenia Research, Volume 92, Issue 1-3, 90-94.
Link
http://www.ncbi.nlm.nih.gov/pubmed/17321111
PI Name
Oliver Freudenreich
Degree
MD
Center
Freedom Trail Clinic, Schizophrenia Program
Institution
Massachusetts General Hospital
Address
25 Staniford Street, 2nd Floor
City or Town
Boston
State or Province
MA
Zip or Postal Code
2114
Country
USA
Email Address
ofreudenreich@partners.org